CURI vs NMAX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

CURI

41.0
AI Score
VS
CURI Wins

NMAX

31.0
AI Score

Investment Advisor Scores

CURI

41score
Recommendation
HOLD

NMAX

31score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric CURI NMAX Winner
Forward P/E 13.7741 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 22.3% 16.5% CURI
Earnings Growth 1400.0% 0.0% CURI
Tradestie Score 41.0/100 31.0/100 CURI
Profit Margin 0.0% -3.1% CURI
Beta 1.00 1.00 Tie
AI Recommendation HOLD EXTENDED Tie

Relative Price Performance (Last 90 Days)

CURI 1M: +20.9% · 3M: +11.4% NMAX 1M: +41.1% · 3M: +39.9%

Current Technical Phase

CURI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $2.84

NMAX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.1% over 20 days), RSI 64

RSI (14): 63.9 · Price: $10.58

Fundamentals Snapshot

Metric CURI NMAX
Market Cap
Forward P/E 9.2 81.4
Trailing P/E 63.2
Revenue (TTM)
Revenue Growth 0.2% 0.2%
Gross Margin 0.6% 0.4%
Operating Margin 0.4% 0.0%
EPS -0.01 0.17
Dividend Yield 0.11%

Frequently Asked Questions

Based on our detailed analysis, CURI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.